Trial · NCT03442764
Adverse events320
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
101 to 120 of 320
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pharyngitis streptococcal | Infections and infestations | Group 1 Mavacamten | 0 | 18 | |
| other | Pharyngitis streptococcal | Infections and infestations | Group 2 Mavacamten | 0 | 21 | |
| other | Pharyngitis streptococcal | Infections and infestations | Combined MAVA Treatment Group (Group 1+ Group 2) | 0 | 39 | |
| other | Pharyngitis streptococcal | Infections and infestations | Placebo | 1 | 19 | |
| other | Sinusitis | Infections and infestations | Group 1 Mavacamten | 1 | 18 | |
| other | Sinusitis | Infections and infestations | Group 2 Mavacamten | 0 | 21 | |
| other | Sinusitis | Infections and infestations | Combined MAVA Treatment Group (Group 1+ Group 2) | 1 | 39 | |
| other | Sinusitis | Infections and infestations | Placebo | 2 | 19 | |
| other | Tooth abscess | Infections and infestations | Group 1 Mavacamten | 2 | 18 | |
| other | Tooth abscess | Infections and infestations | Group 2 Mavacamten | 0 | 21 | |
| other | Tooth abscess | Infections and infestations | Combined MAVA Treatment Group (Group 1+ Group 2) | 2 | 39 | |
| other | Tooth abscess | Infections and infestations | Placebo | 0 | 19 | |
| other | Upper respiratory tract infection | Infections and infestations | Group 1 Mavacamten | 1 | 18 | |
| other | Upper respiratory tract infection | Infections and infestations | Group 2 Mavacamten | 3 | 21 | |
| other | Upper respiratory tract infection | Infections and infestations | Combined MAVA Treatment Group (Group 1+ Group 2) | 4 | 39 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 0 | 19 | |
| other | Urinary tract infection | Infections and infestations | Group 1 Mavacamten | 1 | 18 | |
| other | Urinary tract infection | Infections and infestations | Group 2 Mavacamten | 0 | 21 | |
| other | Urinary tract infection | Infections and infestations | Combined MAVA Treatment Group (Group 1+ Group 2) | 1 | 39 | |
| other | Urinary tract infection | Infections and infestations | Placebo | 0 | 19 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03442764/events?page=6